Christopher C. Woller

Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…

Davis Polk advised the joint book-running managers and the initial purchasers in a Rule 144A/Regulation S offering of €250 million principal amount of senior secured notes due 2026 of WMG…

Davis Polk is advising Emerson on its acquisition of Intelligent Platforms, a division of General Electric. The acquisition is expected to close in the first half of Emerson’s 2019 fiscal…

Davis Polk is advising SS&C Technologies Holdings, Inc. on its $1.5 billion acquisition of Intralinks Holdings, Inc. from affiliates of Siris Capital Group. The transaction is expected…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of…

Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…

Davis Polk advised the joint lead arrangers and joint bookrunners, the administrative agent, and the collateral agent, in connection with the $3.1 billion senior secured credit facilities…

Davis Polk advised the joint lead arrangers and joint bookrunners and the administrative agent in connection with a $400 million senior secured term loan and a $350 million senior secured…

Davis Polk advised the financial advisers to Spotify Technology S.A. in connection with Spotify’s direct listing of its ordinary shares on the New York Stock Exchange. The ordinary shares…